Immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c)

Vaccine

Volumn 26, Issue 48, 2008, Pages 6053-6063

  Romano, Marta ^a   Rindi, Laura ^b   Korf, Hannelie ^a   Bonanni, Daniela ^b   Adnet, Pierre Yves ^a   Jurion, Fabienne ^a   Garzelli, Carlo ^b   Huygen, Kris ^a  

^a PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Mycobacterium tuberculosis; PPE proteins; Tuberculosis vaccine

Indexed keywords

ADJUVANT; BACTERIAL PROTEIN; BCG VACCINE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 2; ISONIAZID; PLASMID DNA; PROLYLPROLYLGLUTAMINE 44; PYRAZINAMIDE; RECOMBINANT PROTEIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; GENE CONSTRUCT; HUMORAL IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BCG VACCINE; CYTOKINES; DNA; EPITOPES; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED STRAINS; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM TUBERCULOSIS; PHYLOGENY; RNA, MESSENGER; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINES, DNA; VACCINES, SYNTHETIC; VIRULENCE FACTORS;

EID: 55049103519     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.025     Document Type: Article

References (46)

1. Rook G., Dheda K., and Zumla A. Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol 5 (2005) 661-667
2. Colditz G., Berkey C., Mosteller F., Brewer T., Wilson M., Burdick E., et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96 (1995) 29-35
3. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., and Burdick E. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 271 (1994) 689-702
4. Fine P.E.M. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 (1995) 1339-1345
5. Kaufmann S.H.E. How can immunology contribute to the control of tuberculosis?. Nat Rev Immunol 1 (2001) 20-30
6. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Eddine A.N., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest 115 (2005) 2472-2479
7. Horwitz M.A. Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect 7 (2005) 947-954
8. Lee S., Jeon B.-Y., Bardarov S., Chen M., Morris S.L., and Jacobs Jr. W.R. Protection elicited by two glutamine auxotrophs of Mycobacterium tuberculosis and in vivo growth phenotypes of the four unique glutamine synthetase mutants in a murine model. Infect Immun 74 (2006) 6491-6495
9. Martin C., Williams A., Hernandez-Pando R., Cardona P.J., Gormley E., Bordat Y., et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24 (2006) 3408-3419
10. Olsen A.W., van Pinxteren L.A.H., Okkels L.M., Rasmussen P.B., and Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infect Immun 69 (2001) 2773-2778
11. Skeiky Y.A.W., Alderson M.R., Ovendale P., Guderian J.A., Brandt L., Dillon D.C., et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172 (2004) 7618-7628
12. Huygen K. Plasmid DNA vaccination. Microbes Infect 7 (2005) 932-938
13. + T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 69 (2001) 681-686
14. McShane H. Prime-boost immunization strategies for infectious diseases. Curr Opin Mol Ther 4 (2002) 23-27
15. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 62 (1994) 2536-2544
16. Dillon D.C., Alderson M.R., Day C.H., Lewinsohn D.M., Coler R., Bement T., et al. Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun 67 (1999) 2941-2950
17. Skeiky Y.A.W., Ovendale P.J., Jen S., Alderson M.R., Dillon D.C., Smith S., et al. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J Immunol 165 (2000) 7140-7149
18. Cole S.T. Learning from the genome sequence of Mycobacterium tuberculosis H37Rv. FEBS Lett 452 (1999) 7-10
19. Demangel C., Brodin P., Cockle P.J., Brosch R., Majlessi L., Leclerc C., et al. Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-Kilodalton culture filtrate protein and ESAT-6. Infect Immun 72 (2004) 2170-2176
20. Le Moigne V., Robreau G., Borot C., Guesdon J.L., and Mahana W. Expression, immunochemical characterization and localization of the Mycobacterium tuberculosis protein p27. Tuberculosis 85 (2005) 213-219
21. Okkels L.M., Brock I., Follmann F., Agger E.M., Arend S.M., Ottenhoff T.H.M., et al. PPE protein (Rv3873) from DNA segment RD1 of Mycobacterium tuberculosis: strong recognition of both specific T-cell epitopes and epitopes conserved within the PPE family. Infect Immun 71 (2003) 6116-6123
22. Sampson S.L., Lukey P., Warren R.M., van Helden P.D., Richardson M., and Everett M.J. Expression, characterization and subcellular localization of the Mycobacterium tuberculosis PPE gene Rv1917c. Tuberculosis 81 (2001) 305-317
23. Chakhaiyar P., Nagalakshmi Y., Aruna B., Murthy K.J., Katoch V.M., and Hasnain S.E. Regions of high antigenicity within the hypothetical PPE major polymorphic tandem repeat open-reading frame, Rv2608, show a differential humoral response and a low T cell response in various categories of patients with tuberculosis. J Infect Dis 190 (2004) 1237-1244
24. Choudhary R.K., Mukhopadhyay S., Chakhaiyar P., Sharma N., Murthy K.J.R., Katoch V.M., et al. PPE antigen Rv2430c of Mycobacterium tuberculosis induces a strong B-cell response. Infect Immun 71 (2003) 6338-6343
25. Singh K.K., Dong Y., Patibandla S.A., McMurray D.N., Arora V.K., and Laal S. Immunogenicity of the Mycobacterium tuberculosis PPE55 (Rv3347c) protein during incipient and clinical tuberculosis. Infect Immun 73 (2005) 5004-5014
26. Rindi L., Lari N., and Garzelli C. Search for genes potentially involved in Mycobacterium tuberculosis virulence by mRNA differential display. Biochem Biophys Res Commun 258 (1999) 94-101
27. Rindi L., Peroni I., Lari N., Bonanni D., Tortoli E., and Garzelli C. Variation of the expression of Mycobacterium tuberculosis ppe44 gene among clinical isolates. FEMS Immunol Med Microbiol 51 (2007) 381-387
28. Mollenkopf H.J., Grode L., Mattow J., Stein M., Mann P., Knapp B., et al. Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG Prime-Rv3407 DNA boost vaccination against tuberculosis. Infect Immun 72 (2004) 6471-6479
29. Bonanni D., Rindi L., Lari N., and Garzelli C. Immunogenicity of mycobacterial PPE44 (Rv2770c) in Mycobacterium bovis BCG-infected mice. J Med Microbiol 54 (2005) 443-448
30. Huygen K., Abramowicz D., Vandenbussche P., Jacobs F., De Bruyn J., Kentos A., et al. Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice. Infect Immun 60 (1992) 2880-2886
31. Roupie V., Romano M., Zhang L., Korf H., Lin M.Y., Franken K.L.M.C., et al. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect Immun 75 (2007) 941-949
32. Scanga C.A., Mohan V.P., Yu K., Joseph H., Tanaka K., Chan J., et al. Depletion of CD4+ T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon {gamma} and nitric oxide synthase 2. J Exp Med 192 (2000) 347-358
33. Snewin V.A., Gares M.-P., Gaora P.O., Hasan Z., Brown I., and Young D.B. Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect Immun 67 (1999) 4586-4593
34. D'Souza S., Rosseels V., Denis O., Tanghe A., De Smet N., Jurion F., et al. Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect Immun 70 (2002) 3681-3688
35. Aichele P., Brduscha-Riem K., Oehen S., Odermatt B., Zinkernagel R.M., Hengartner H., and Pircher H. Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity 6 (1997) 519-529
36. b restricted cytolytic T cell activity against a putative phosphate transport receptor of M. tuberculosis. J Immunol 172 (2004) 6913-6921
37. Lindblad E.B., Elhay M.J., Silva R., Appelberg R., and Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 65 (1997) 623-629
38. Feller D.C., and de La Cruz V.F. Identifying antigenic T-cell sites. Nature 349 (1991) 720-721
39. Denis O., Tanghe A., Palfliet K., Jurion F., Van den Berg T.P., Vanonckelen A., et al. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect Immun 66 (1998) 1527-1533
40. van Pinxteren L.A.H., Cassidy J.P., Smedegaard B.H.C., Agger E.M., and Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 30 (2000) 3689-3698
41. Shi L., North R.J., and Gennaro M.L. Effect of growth state on transcription levels of genes encoding major secreted antigens of Mycobacterium tuberculosis in the mouse lung. Infect Immun 72 (2004) 2420-2424
42. Hebert A.M., Talarico S., Yang D., Durmaz R., Marrs C.F., Zhang L., et al. DNA polymorphisms in the pepA and PPE18 genes among clinical strains of Mycobacterium tuberculosis: implications for vaccine efficacy. Infect Immun 75 (2007) 5798-5805
43. Anonymous. European concerted action on new generation genetic markers and techniques for the epidemiology and control of tuberculosis. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis 12 (2006) 736-743
44. Abebe F., and Bjune G. The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Guérin (BCG) vaccines: is there a link?. Clin Exp Immunol 145 (2006) 389-397
45. Skeiky Y.A., Alderson M.R., Ovendale P.J., Lobet Y., Dalemans W., Orme I.M., et al. Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41. Vaccine 23 (2005) 3937-3945
46. Gey van Pittius N.C., Sampson S.L., Lee H., Kim Y., van Helden P.D., and Warren R.M. Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions. BMC Evol. Biol. 6 (2006) 95